Press Releases

GlobeNewswire, Inc.

Following alignment discussions with FDA, BLA completion for HR BCG-unresponsive NMIBC is expected fourth quarter 2026 PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC...

GlobeNewswire, Inc.

BOSTON, May 07, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced the appointment of Nelson Azoulay as Chief Business...

Washington State Office of Attorney General

Attorney General Nick Brown and a multistate coalition have successfully resolved a lawsuit stopping the Trump administration from unlawfully taking homeland security funding away from states that would not comply with the administration’s...

GlobeNewswire, Inc.

WESTON, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Students and working adults across Massachusetts will soon have expanded access to career training in healthcare and IT through a new partnership between MedCerts, a nationally recognized leader in...

City of Boston

Bank On Boston is partnering with Northeastern University and other leading research institutions, including the Bogle Foundation, University of Chicago Booth School of Business, Harvard Business School, and J-PAL at MIT, to explore how young...

GlobeNewswire, Inc.

Reported positive topline data from Phase 3 X-TOLE2 study of azetukalner in FOS in March and anticipate NDA submission in Q3 2026 Five additional Phase 3 studies of azetukalner continue to enroll in epilepsy and depression indications with Phase 3...

GlobeNewswire, Inc.

Advancing next-generation γδ T cell engager platform with initial animal data expected in 2026 Reported glioblastoma (GBM) data showing ~97% improvement in progression-free survival vs. standard-of-care; updated median overall survival (mOS) data...

GlobeNewswire, Inc.

TX45 APEX Phase 2 patient enrollment in PH-HFpEF is nearing completion with topline results anticipated in late Q4 2026 or early Q1 2027 TX2100 advanced into Phase 1a healthy volunteer clinical trial in February 2026 as a potential treatment for...

GlobeNewswire, Inc.

Successfully dosed all four planned healthy volunteer SAD cohorts of ongoing ABS-201™ HEADLINE trial; well-tolerated with favorable emerging safety data Preliminary pharmacokinetic (PK) modeling from HEADLINE trial supports ABS-201's targeted...

GlobeNewswire, Inc.

-- On track to file IND and/or CTA for PM577 in Wilson Disease in H1 2026 and for PM647 in AATD mid-2026; initial clinical data from both programs expected in 2027 -- -- Continued regulatory dialogue with the FDA toward BLA filing for PM359 in CGD...

GlobeNewswire, Inc.

VANCOUVER, British Columbia, May 07, 2026 (GLOBE NEWSWIRE) -- VR Resources Limited (“VR” or the “Company”, TSX.V: VRR, FSE: 5VR; OTCQB: VRRCF) is pleased to announce that the drill program is underway on its New Boston moly-tungsten-copper-silver...

Office of the Attorney General California Department of Justice

Trump Administration drops appeal of final order, permanently and fully resolving case in California’s favor OAKLAND – California Attorney General Rob Bonta today announced the successful resolution of a multistate lawsuit to stop the Trump...

GlobeNewswire, Inc.

Strong start to the year with worldwide revenue of $377.3 million in the first quarter 2026 GAAP fully diluted earnings per share of $1.80, compared to $1.02 in the first quarter of 2025 Adjusted fully diluted earnings per share of $1.46, compared...

GlobeNewswire, Inc.

Interim clinical data from GFORCE-1 trial of NEK7-directed MGD MRT-8102 demonstrated profound CRP reductions in subjects with elevated CVD risk; readout of expanded GFORCE-1 trial in subjects with elevated CVD risk anticipated in H2 2026 Company...

GlobeNewswire, Inc.

Phase 2a follow-up period data for RAP-219 in focal onset seizures (FOS) demonstrated sustained seizure reduction, including a 90% median reduction in clinical seizures over baseline in weeks 9-12 RAP-219 Phase 2 trial in bipolar mania topline...

GlobeNewswire, Inc.

Phase 1 clinical trial of SL-325 enrollment complete; data expected in the second quarter of 2026 – Phase 2 clinical trial of SL-325 in patients with Crohn’s disease expected to initiate in the third quarter of 2026 – AUSTIN, Texas and DURHAM,...

GlobeNewswire, Inc.

BOSTON, April 30, 2026 (GLOBE NEWSWIRE) -- The Boston Beer Company, Inc. (NYSE: SAM), today reported financial results for the first quarter ended March 28, 2026. Key results were: First Quarter 2026 Summary: Depletions decreased 4% and shipments...

GlobeNewswire, Inc.

One-Year Cohort 1 Data and Initial Cohort 2 Data from RIDGE™-1 Phase 1b/2 Trial of TN-401 for PKP2-Associated ARVC to be Presented at ASGCT 2026 New Data from Both Cohorts of the MyPEAK™-1 Phase 1b/2 Trial of TN-201 for Adults with...

GlobeNewswire, Inc.

ATLANTA and BOSTON, May 06, 2026 (GLOBE NEWSWIRE) -- ABLi Therapeutics (“ABLi”), a biotechnology company developing therapeutics to address diseases that arise from activation of Abelson Tyrosine Kinases (c-Abl kinases), announces the appointment...

GlobeNewswire, Inc.

BOSTON, April 30, 2026 (GLOBE NEWSWIRE) -- On April 26, 30 students and six chaperones from the Boston area returned from Panama after a week spent finishing two new classrooms, painting four murals, and refurbishing two playgrounds, working...